UTHEALTH HOME    ABOUT SBMI    A-Z    WEBMAIL    INSIDE THE UNIVERSITY
FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Kinase Fusion Gene Summary

leaf

Kinase Fusion Gene Sample Information

leaf

Kinase Fusion ORF Analysis

leaf

Kinase Fusion Amino Acid Sequences

leaf

Multiple Sequence Alignment of All Fusion Protein Isoforms

leaf

Kinase Fusion Protein Functional Features

leaf

Kinase Fusion Protein Structures

leaf

Comparison of Fusion Protein Isoforms

leaf

Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB

leaf

pLDDT Scores and Difference Analysis of pLDDT Scores Between the Active Sites (Best) and Non-Active Sites.

leaf

Ramachandran Plot of Kinase Fusion Protein Structure

leaf

Potential Active Site Information

leaf

Virtual Screening Results

leaf

Kinase-Substrate Information

leaf

Related Drugs with This Kinase Fusion Protein

leaf

Related Disease with This Kinase Fusion Protein

leaf

Clinical Trials of the Found Drugs/Small Molecules

Kinase Fusion Gene:MCM5_LYN

Kinase Fusion Protein Summary

check button Kinase Fusion gene summary
Kinase Fusion partner gene informationKinase Fusion gene name: MCM5_LYN
KinaseFusionDB ID: KFG3732
FusionGDB2.0 ID: KFG3732
HgeneTgene
Gene symbol

MCM5

LYN

Gene ID

4174

4067

Gene nameminichromosome maintenance complex component 5LYN proto-oncogene, Src family tyrosine kinase
SynonymsCDC46|MGORS8|P1-CDC46JTK8|SAIDV|p53Lyn|p56Lyn
Cytomap

22q12.3

8q12.1

Type of geneprotein-codingprotein-coding
DescriptionDNA replication licensing factor MCM5CDC46 homologMCM5 minichromosome maintenance deficient 5, cell division cycle 46minichromosome maintenance deficient 5 (cell division cycle 46)tyrosine-protein kinase Lynlck/Yes-related novel protein tyrosine kinasev-yes-1 Yamaguchi sarcoma viral related oncogene homolog
Modification date2024040320240411
UniProtAcc

P33992

P07948

Ensembl transtripts involved in fusion geneENST idsENST00000216122, ENST00000382011, 
ENST00000465557, 		ENST00000420292, 
ENST00000519728, ENST00000520220, 
Context (manual curation of fusion genes in KinaseFusionDB)

PubMed: MCM5 [Title/Abstract] AND LYN [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)MCM5(35799535)-LYN(56910905), # samples:3
check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneMCM5

GO:0006268

DNA unwinding involved in DNA replication

22474384

TgeneLYN

GO:0000077

DNA damage checkpoint signaling

10891478

TgeneLYN

GO:0006468

protein phosphorylation

11517336

TgeneLYN

GO:0006974

DNA damage response

11517336

TgeneLYN

GO:0018108

peptidyl-tyrosine phosphorylation

7682714|11782428

TgeneLYN

GO:0030222

eosinophil differentiation

11823534

TgeneLYN

GO:0038043

interleukin-5-mediated signaling pathway

11823534

TgeneLYN

GO:0043410

positive regulation of MAPK cascade

10891478

TgeneLYN

GO:0046777

protein autophosphorylation

7682714


check buttonKinase Fusion gene breakpoints across MCM5 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonKinase Fusion gene breakpoints across LYN (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Kinase Fusion Gene Sample Information

check buttonKinase Fusion gene information.
check button Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceSampleHgeneHchrHbpTgeneTchrTbp
ChimerDB4TCGA-25-1329-01AMCM5chr22

35799535

LYNchr8

56910905

ChimerDB4TCGA-25-1329MCM5chr22

35799535

LYNchr8

56910904



Top

Kinase Fusion ORF Analysis


check buttonKinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB.
HenstTenstHgeneHchrHbpTgeneTchrTbpSeq length
(transcript)		Seq length
(amino acids)

Top

Kinase Fusion Amino Acid Sequences


check button For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq

Multiple Sequence Alignment of All Fusion Protein Isoforms



Top

Kinase Fusion Protein Functional Features


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr22:35799535/chr8:56910905)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
MCM5

P33992

LYN

P07948

FUNCTION: Acts as a component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232, PubMed:16899510). The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity (PubMed:32453425). {ECO:0000269|PubMed:16899510, ECO:0000269|PubMed:32453425, ECO:0000269|PubMed:34694004, ECO:0000269|PubMed:34700328, ECO:0000269|PubMed:35585232}.FUNCTION: Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending on the context. Required for the initiation of the B-cell response, but also for its down-regulation and termination. Plays an important role in the regulation of B-cell differentiation, proliferation, survival and apoptosis, and is important for immune self-tolerance. Acts downstream of several immune receptors, including the B-cell receptor, CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4. Plays a role in the inflammatory response to bacterial lipopolysaccharide. Mediates the responses to cytokines and growth factors in hematopoietic progenitors, platelets, erythrocytes, and in mature myeloid cells, such as dendritic cells, neutrophils and eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an important role in integrin signaling. Regulates cell proliferation, survival, differentiation, migration, adhesion, degranulation, and cytokine release. Down-regulates signaling pathways by phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIM), that then serve as binding sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1, that modulate signaling by dephosphorylation of kinases and their substrates. Phosphorylates LIME1 in response to CD22 activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A, CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B, SYK and TEC. Promotes phosphorylation of SIRPA, PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates phosphorylation of the BCR-ABL fusion protein. Required for rapid phosphorylation of FER in response to FCER1 activation. Mediates KIT phosphorylation. Acts as an effector of EPOR (erythropoietin receptor) in controlling KIT expression and may play a role in erythroid differentiation during the switch between proliferation and maturation. Depending on the context, activates or inhibits several signaling cascades. Regulates phosphatidylinositol 3-kinase activity and AKT1 activation. Regulates activation of the MAP kinase signaling cascade, including activation of MAP2K1/MEK1, MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates activation of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-72'. Kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation. Phosphorylates SCIMP on 'Tyr-107'; this enhances binding of SCIMP to TLR4, promoting the phosphorylation of TLR4, and a selective cytokine response to lipopolysaccharide in macrophages (By similarity). Phosphorylates CLNK (By similarity). Phosphorylates BCAR1/CAS and NEDD9/HEF1 (PubMed:9020138). {ECO:0000250|UniProtKB:P25911, ECO:0000269|PubMed:10574931, ECO:0000269|PubMed:10748115, ECO:0000269|PubMed:10891478, ECO:0000269|PubMed:11435302, ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:11825908, ECO:0000269|PubMed:14726379, ECO:0000269|PubMed:15795233, ECO:0000269|PubMed:16467205, ECO:0000269|PubMed:17640867, ECO:0000269|PubMed:17977829, ECO:0000269|PubMed:18056483, ECO:0000269|PubMed:18070987, ECO:0000269|PubMed:18235045, ECO:0000269|PubMed:18577747, ECO:0000269|PubMed:18802065, ECO:0000269|PubMed:19290919, ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:7687428, ECO:0000269|PubMed:9020138}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page

* Minus value of BPloci means that the break pointn is located before the CDS.

check button - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt).
PartnerHgeneeneHbpTgeneeneTbpENSTBPexonTotalExonProtein feature lociBPlociTotalLenFeatureNote


check button - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt).
PartnerHgeneeneHbpTgeneeneTbpENSTBPexonTotalExonProtein feature lociBPlociTotalLenFeatureNote


Top

Kinase-Substrate Information of MCM5_LYN


check button Phosphorylation target of the kinase
(phosphosite, 03-17-2024)
KinaseKinase UniProt AccKinase speciesSubstrateSubstrate UniProt AccSubstrate phosphorylated residuesSubstrate phosphorylated sites (+/-7AA)Domain
LYNP07948humanNMT1P30419Y180YTLLNENyVEDDDNMNMT
LYNP07948humanABL1P00519Y393RLMtGDtytAHAGAkPK_Tyr_Ser-Thr
LYNP07948humanYY1P25490Y8MASGDTLyIATDGSE
LYNP07948humanAKAP8O43823Y53TTGATySyGPASWEA
LYNP07948humanGCSAMQ8N6F7Y106sGNsAEEyyENVPCkHGAL
LYNP07948humanACLYP53396Y682sRtTDGVyEGVAIGGLigase_CoA
LYNP07948humanRGS16O15492Y177RFLkSPAyRDLAAQARGS
LYNP07948humanSLC4A1P02730Y21ENLEQEEyEDPDIPE
LYNP07948humanSLC4A1P02730Y8MEELQDDyEDMMEEN
LYNP07948humanPTPN6P29350Y564sKHkEDVyENLHTkN
LYNP07948humanFCGR2AP12318Y304tDDDKNIyLTLPPND
LYNP07948humanACLYP53396Y131YATREGDyVLFHHEG
LYNP07948humanCSF2RBP32927Y882KALKQQDyLSLPPWE
LYNP07948humanRMDN3Q96TC7Y176DAESEGGytTANAEs
LYNP07948humanCSF2RBP32927Y822VLQQVGDyCFLPGLG
LYNP07948humanTRIM28Q13263Y517PGsTtEDyNLIVIER
LYNP07948humanCASP8Q14790Y380tDsEEQPyLEMDLSsPeptidase_C14
LYNP07948humanSYKP43405Y323sTVsFNPyEPELAPW
LYNP07948humanCSF2RBP32927Y466ALRFCGIyGyRLRRk
LYNP07948humanCASP8Q14790Y448TILTEVNyEVSNKDDPeptidase_C14
LYNP07948humanCD19P15391Y500TSLGsQsyEDMRGIL
LYNP07948humanIRF5Q13568Y335QLQGQDLyAIRLCQCIRF-3
LYNP07948humanLY96Q9Y6Y9Y131IKFSKGKyKCVVEAIE1_DerP2_DerF2
LYNP07948humanYY1P25490Y383IHtGDrPyVCPFDGCzf-C2H2
LYNP07948humanSLC4A1P02730Y359AKPDssFyKGLDLNG
LYNP07948humanABL1P00519Y128SLEKHSWyHGPVSRNSH2
LYNP07948humanAKAP8O43823Y154RPsySyDyEFDLGSD
LYNP07948humanCDKN1BP46527Y88kGsLPEFyyRPPRPP
LYNP07948humanFCGR2BP31994Y292GAENTITysLLMHPD
LYNP07948humanTRIM28Q13263Y449PMEVQEGyGFGsGDD
LYNP07948humanAKAP8O43823Y539IVkMLEkyLKGEDPFAKAP95
LYNP07948humanPTENP60484Y240RREDKFMyFEFPQPLPTEN_C2
LYNP07948humanLAT2Q9GZY6Y95EDPASSRyQNFSkGsLAT2
LYNP07948humanCBLP22681Y371TQEQyELyCEMGSTF
LYNP07948humanABL1P00519Y226KRNKPtVyGVsPNyD
LYNP07948humanLY96Q9Y6Y9Y22FTEAQKQyWVCNSSD
LYNP07948humanABL1P00519Y115QGWVPsNyItPVNSL
LYNP07948humanGCSAMQ8N6F7Y128LGGTEtEySLLHMPSHGAL
LYNP07948humanSYKP43405Y348LPMDtEVyEsPyADP
LYNP07948humanGCSAMQ8N6F7Y107GNsAEEyyENVPCkAHGAL
LYNP07948humanIKBKBO14920Y188sFVGTLQyLAPELLEPkinase
LYNP07948humanACLYP53396Y252EAyPEEAyIADLDAkCitrate_bind
LYNP07948humanABL1P00519Y215GLITTLHyPAPKRNK
LYNP07948humanABL1P00519Y70PNLFVALyDFVAsGDSH3_1
LYNP07948humanPEAK1Q9H792Y635IVINPNAyDNLAIyK
LYNP07948humanCDK4P11802Y17AEIGVGAyGTVYkARPkinase
LYNP07948humanAKAP8O43823Y146CLPEHNPyRPsySyD
LYNP07948humanAKAP8O43823Y170NGsFGGQySECRDPA
LYNP07948humanSYKP43405Y526LRADENyykAQtHGKPK_Tyr_Ser-Thr
LYNP07948humanSOCS1O15524Y80LLDACGFyWGPLSVHSH2
LYNP07948humanLYNP07948Y508ytAtEGQyQQQP___
LYNP07948humanPTGS2P35354Y120PPTYNADyGYKSWEA
LYNP07948humanGLO1Q04760Y136GIAVPDVysACkRFEGlyoxalase
LYNP07948humanLAT2Q9GZY6Y119DPIAMEyyNWGRFSkLAT2
LYNP07948humanSLC4A1P02730Y904EEEGRDEyDEVAMPV
LYNP07948humanFCGR2CP31995Y310tDDDKNIyLTLPPND
LYNP07948humanBCRP11274Y177ADAEKPFyVNVEFHH
LYNP07948humanACLYP53396Y659yRPGsVAyVSRsGGM
LYNP07948humanBTKQ06187Y223LKKVVALyDyMPMNASH3_1
LYNP07948humanAKAP8O43823Y51SVTTGATySyGPASW
LYNP07948humanCD19P15391Y531HEEDADsyENMDNPD
LYNP07948humanABL1P00519Y139VSRNAAEyLLsSGINSH2
LYNP07948humanLAT2Q9GZY6Y110RHGsEEAyIDPIAMELAT2
LYNP07948humanIRF5Q13568Y313PSDkQRFyTNQLLDVIRF-3
LYNP07948humanLYNP07948Y397RVIEDNEytAREGAkPK_Tyr_Ser-Thr
LYNP07948humanAKAP8O43823Y152PyRPsySyDyEFDLG
LYNP07948humanAKAP8O43823Y150HNPyRPsySyDyEFD
LYNP07948humanPTPN6P29350Y536QkGQEsEyGNItyPP
LYNP07948humanSLAMF1Q13291Y327ETNSITVyASVTLPE
LYNP07948humanGCSAMQ8N6F7Y86tysEELCytLINHRVHGAL
LYNP07948humanRGS16O15492Y168TLMEKDSyPRFLkSPRGS
LYNP07948humanABL1P00519Y172LRyEGRVyHyRINTASH2
LYNP07948humanAKAP8O43823Y80PAMHMASyGPEPCTD
LYNP07948humanLAT2Q9GZY6Y136EDDDANsyENVLICKLAT2
LYNP07948humanLAT2Q9GZY6Y118IDPIAMEyyNWGRFSLAT2
LYNP07948humanSYKP43405Y352tEVyEsPyADPEEIR
LYNP07948humanACLYP53396Y384VRrGGPNyQEGLrVMCitrate_bind
LYNP07948humanACLYP53396Y227KVDATADyICkVkWG
LYNP07948humanHCLS1P14317Y222MEAPttAykkTTPIE
LYNP07948humanBTKQ06187Y551RYVLDDEytsSVGSkPK_Tyr_Ser-Thr
LYNP07948humanABL1P00519Y185TAsDGKLyVsSESRFSH2
LYNP07948humanGCSAMQ8N6F7Y80QDNVDQtysEELCytHGAL
LYNP07948humanSYKP43405Y525ALRADENyykAQtHGPK_Tyr_Ser-Thr
LYNP07948humanIKBKBO14920Y199ELLEQQKyTVTVDYWPkinase
LYNP07948humanCSF2RBP32927Y468RFCGIyGyRLRRkWE
LYNP07948humanLASP1Q14847Y171IPtsAPVyQQPQQQP
LYNP07948humanYY1P25490Y254sPPDySEyMTGkKLP
LYNP07948humanWASP42768Y291AEtsKLIyDFIEDQGPBD
LYNP07948humanSLCO1B1Q9Y6L6Y645VLyIILIyAMKKKYQTM
LYNP07948humanMCM7P33993Y600WASkDAtyTSARtLLMCM_lid
LYNP07948humanDAPP1Q9UN19Y139kVEEPsIyEsVRVHT
LYNP07948humanTRIM28Q13263Y458FGsGDDPyssAEPHV
LYNP07948humanAKAP8O43823Y311KRkQFQLyEEPDTkL
LYNP07948humanAKAP8O43823Y436TVEFLQEyIVNRNKKAKAP95
LYNP07948humanPPP1R8Q12972Y335NEPKKKKyAKEAWPG
LYNP07948humanIKBKGQ9Y6K9Y374PLPPAPAyLssPLAL


check button Biological Network Integration of This Kinase and Substrates
(GeneMANIA website)

check button Enriched GO biological processes of the phosphorylation target genes of the kinase
KinaseGOIDGO termP.adjust
LYNIDDescription0.00e+00
LYNGO:0050853B cell receptor signaling pathway1.46e-10
LYNGO:0050851antigen receptor-mediated signaling pathway5.71e-10
LYNGO:0002429immune response-activating cell surface receptor signaling pathway1.89e-09
LYNGO:0002768immune response-regulating cell surface receptor signaling pathway3.80e-09
LYNGO:0002237response to molecule of bacterial origin6.44e-09
LYNGO:0002366leukocyte activation involved in immune response1.06e-08
LYNGO:0002275myeloid cell activation involved in immune response1.06e-08
LYNGO:0002263cell activation involved in immune response1.06e-08
LYNGO:0002443leukocyte mediated immunity5.29e-08
LYNGO:0002757immune response-activating signaling pathway5.65e-08
LYNGO:0042113B cell activation6.82e-08
LYNGO:0043299leukocyte degranulation7.74e-08
LYNGO:0002764immune response-regulating signaling pathway8.18e-08
LYNGO:0002274myeloid leukocyte activation2.95e-07
LYNGO:0002279mast cell activation involved in immune response2.95e-07
LYNGO:0038093Fc receptor signaling pathway2.95e-07
LYNGO:0032496response to lipopolysaccharide3.87e-07
LYNGO:0002444myeloid leukocyte mediated immunity4.51e-07
LYNGO:0071216cellular response to biotic stimulus5.48e-07
LYNGO:0050854regulation of antigen receptor-mediated signaling pathway6.50e-07
LYNGO:0045576mast cell activation8.13e-07
LYNGO:1902105regulation of leukocyte differentiation2.49e-06
LYNGO:0030183B cell differentiation3.50e-06
LYNGO:0070661leukocyte proliferation4.79e-06
LYNGO:0002703regulation of leukocyte mediated immunity4.97e-06
LYNGO:1903131mononuclear cell differentiation5.42e-06
LYNGO:0045936negative regulation of phosphate metabolic process7.73e-06
LYNGO:0010563negative regulation of phosphorus metabolic process7.73e-06
LYNGO:0043303mast cell degranulation8.10e-06
LYNGO:0018108peptidyl-tyrosine phosphorylation9.04e-06
LYNGO:0002697regulation of immune effector process9.04e-06
LYNGO:0018212peptidyl-tyrosine modification9.04e-06
LYNGO:0002448mast cell mediated immunity9.38e-06
LYNGO:0050855regulation of B cell receptor signaling pathway1.01e-05
LYNGO:0002886regulation of myeloid leukocyte mediated immunity1.05e-05
LYNGO:0038095Fc-epsilon receptor signaling pathway1.36e-05
LYNGO:1903706regulation of hemopoiesis1.37e-05
LYNGO:0002433immune response-regulating cell surface receptor signaling pathway involved in phagocytosis1.48e-05
LYNGO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis1.48e-05
LYNGO:0046651lymphocyte proliferation1.54e-05
LYNGO:0030098lymphocyte differentiation1.57e-05
LYNGO:0032943mononuclear cell proliferation1.74e-05
LYNGO:0031400negative regulation of protein modification process1.75e-05
LYNGO:0050864regulation of B cell activation1.75e-05
LYNGO:0045055regulated exocytosis2.63e-05
LYNGO:0050730regulation of peptidyl-tyrosine phosphorylation2.89e-05
LYNGO:0002431Fc receptor mediated stimulatory signaling pathway2.92e-05
LYNGO:0038094Fc-gamma receptor signaling pathway3.22e-05
LYNGO:0006909phagocytosis3.22e-05

Top

Related Drugs to MCM5_LYN


check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

check button Distribution of the number of studies mentioning MCM5-LYN and kinase inhibitors the PubMed Abstract (04-01-2024)

Fusion gene - drug pair 1Fusion gene - drug pair 2PMIDPublication dateDOIStudy title

Top

Related Diseases to MCM5_LYN


check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Related diseases from the literature mentioned this fusion gene and drug.
(PubMed, 04-01-2024)
MeSH IDMeSH term

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource


Top

Clinical Trials of the Found Drugs/Small Molecules


check button Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024)

check button Clinical Trials from clinicaltrials.gov (06-17-2024)

Fusion GeneKinase InhibitorNCT IDStudy StatusPhasesDisease# EnrolmentDate